UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation

Endocrine Journal, 2020, Vol.67(1), pp.99-106

2020

Volltextzugriff (PDF)

GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells

Journal of Atherosclerosis and Thrombosis, 2019/02/01, Vol.26(2), pp.183-197

2019

Volltextzugriff (PDF)

Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro

Diabetology international, 2021-10, Vol.12 (4), p.389-398

2021

Volltextzugriff (PDF)

High-mobility group box 2 protein is essential for the early phase of adipogenesis

Biochemical and biophysical research communications, 2021-06, Vol.557, p.97-103

2021

Volltextzugriff (PDF)

Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth

Diabetes (New York, N.Y.), 2014-11, Vol.63 (11), p.3891-3905

2014

Volltextzugriff (PDF)

Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation

Endocrinology (Philadelphia), 2018-04, Vol.159 (4), p.1774-1792

2018

Volltextzugriff (PDF)

Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line

PloS one, 2016-10, Vol.11 (10), p.e0164131-e0164131

2016

Volltextzugriff (PDF)

Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth

Diabetology international, 2022-07, Vol.13 (3), p.480-492

2022

Volltextzugriff (PDF)

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth

PloS one, 2015-10, Vol.10 (10), p.e0139709

2015

Volltextzugriff (PDF)

Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression

Journal of diabetes investigation, 2020-09, Vol.11 (5), p.1137-1149

2020

Volltextzugriff (PDF)

Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury

Cardiovascular diabetology, 2014-11, Vol.13 (1), p.154-154, Article 154

2014

Volltextzugriff (PDF)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Biochemistry and biophysics reports, 2019-07, Vol.18, p.100640-100640, Article 100640

2019

Volltextzugriff (PDF)

HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells

The Journal of steroid biochemistry and molecular biology, 2018-09, Vol.182, p.21-26

2018

Volltextzugriff (PDF)

Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet

Heliyon, 2020-11, Vol.6 (11), p.e05431-e05431, Article e05431

2020

Volltextzugriff (PDF)

Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes

Biochemistry and biophysics reports, 2019-03, Vol.17, p.177-181

2019

Volltextzugriff (PDF)

HMGA1a Induces Alternative Splicing of the Estrogen Receptor- α lpha Gene by Trapping U1 snRNP to an Upstream Pseudo-5' Splice Site

Frontiers in molecular biosciences, 2018-06, Vol.5, p.52-52

2018

Volltextzugriff (PDF)

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Attenuates Prostate Cancer Cell Proliferation via Phosphorylation of MKP-1

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation

Endocrinology (Philadelphia), 2017-12, Vol.158 (12), p.4218-4232

2017

Volltextzugriff (PDF)

Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation

Endocrinology (Philadelphia), 2018-04, Vol.159 (4), p.1774-1792

2018

Volltextzugriff (PDF)

476-P: Pemafibrate, a PPAR Alpha Agonist, Attenuates Neointima Formation after Vascular Injury in Nondiabetic and Diabetic Mice

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

1954-P: Combined Treatment with Exendin-4 and Metformin Attenuates Breast Cancer Growth

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Forced Expressed GLP-1R Attenuates Prostate Cancer Growth

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

SGLT2 Inhibitor Ipragliflozin Induces Breast Cancer Apoptosis via Membrane Hyperpolarization and Mitochondria Dysfunction

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Combined Treatment with Exendin-4 and Metformin Attenuates Breast Cancer Growth

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

1955-P: GLP-1R Activation Attenuates Prostate Cancer Growth via Inhibiting Cell Cycle Progression

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(60)
Berichte
(1)

Sprache

Englisch
(60)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation

GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells

Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro

High-mobility group box 2 protein is essential for the early phase of adipogenesis

Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth

Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation

Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line

Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth

Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression

Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells

Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet

Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes

HMGA1a Induces Alternative Splicing of the Estrogen Receptor- α lpha Gene by Trapping U1 snRNP to an Upstream Pseudo-5' Splice Site

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Attenuates Prostate Cancer Cell Proliferation via Phosphorylation of MKP-1

Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation

Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation

476-P: Pemafibrate, a PPAR Alpha Agonist, Attenuates Neointima Formation after Vascular Injury in Nondiabetic and Diabetic Mice

1954-P: Combined Treatment with Exendin-4 and Metformin Attenuates Breast Cancer Growth

Forced Expressed GLP-1R Attenuates Prostate Cancer Growth

SGLT2 Inhibitor Ipragliflozin Induces Breast Cancer Apoptosis via Membrane Hyperpolarization and Mitochondria Dysfunction

Combined Treatment with Exendin-4 and Metformin Attenuates Breast Cancer Growth

1955-P: GLP-1R Activation Attenuates Prostate Cancer Growth via Inhibiting Cell Cycle Progression

Suchergebnisse filtern